The recurrence time of the low-risk group was significantly longer than that of the high-risk group, suggesting that the decreased expression of ToPo II and high expression of MRP and GST-π was associated with tumor invasion, recurrence and poor prognosis, and this conclusion had been confirmed in ovarian cancer [21]. The gene discussed is GSTP1; the disease is ovarian carcinoma.